Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript - Results of Polish multicentre study

Hematological Oncology

Volumn 28, Issue 2, 2010, Pages 93-97

  Helbig, Grzegorz ^a   Moskwa, Andrzej ^b   Hus, Marek ^c   Piszcz, Jarosław ^d   Swiderska, Alina ^b   Urbanowicz, Alina ^b   Całbecka, Małgorzata ^e   Gajkowska, Justyna ^e   Seferyńska, Ilona ^f   Hałasz, Magdalena ^g   Woszczyk, Dariusz ^h   Markiewicz, Miroslaw ^a   Krzemień, Sławomira ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Provincial Hospital   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^e Provincial Hospital   (Poland)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

^g Provincial Hospital Rzeszow   (Poland)

^h Provincial Hospital   (Poland)

Author keywords

Chronic eosinophilic leukaemia; FIP1L1 PDGFRA; Hypereosinophilic syndrome; Imatinib

Indexed keywords

IMATINIB; INTERLEUKIN 5; TRYPTASE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; EOSINOPHIL COUNT; EOSINOPHILIC LEUKEMIA; FEMALE; FIP1L1 GENE; GENE FUSION; GENETIC TRANSCRIPTION; HUMAN; HYPEREOSINOPHILIC SYNDROME; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PDGFRA GENE; POLAND; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROLOGY; SPLENOMEGALY; THROMBOCYTE COUNT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COUGH; FEMALE; HEPATOMEGALY; HUMANS; HYPEREOSINOPHILIC SYNDROME; INCIDENTAL FINDINGS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PLATELET COUNT; POLAND; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RNA, MESSENGER; RNA, NEOPLASM; SPLENOMEGALY; YOUNG ADULT;

EID: 77953258448     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.919     Document Type: Article

References (11)

1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1-27
2. Cools J, De Angelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214
3. Mitelman F. An International System for Human Cytogenetic Nomenclature. S. Karger: Basel, 1995
4. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-T98-3936. Leukemia 2003; 17: 2257-2317
5. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92: 1173-1179
6. Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. Molecular characterization of the idiopathic hypereosinophilic syndorme (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005; 19: 792-798
7. Pardanani A, Ketterling RP, Li CY, et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006; 30: 965-970
8. Jovanovic J, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular response and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood 2007; 109: 4635-4641
9. Metzgeroth G, Walz C, Erben P, et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome-a phase-II study. Br J Haematol 2008; 143: 707-715
10. Helbig G, Stella-Hołowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 2008; 141: 200-204
11. Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117: 1292-1302